ALK and non-small cell lung carcinoma: In vitro models suggest that crizotinib is five times more potent in inhibiting ROS1 than ALK, and this may explain the longer responses achieved in ROS1-rearranged NSCLC compared with ALK-rearranged ones [5,34].